ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

CRISPR antibiotics company raises cash

by Ryan Cross
November 20, 2017 | APPEARED IN VOLUME 95, ISSUE 46

Locus Biosciences has raised $19 million in a series A funding round to develop antibiotics with CRISPR. While most gene-editing companies are working with CRISPR/Cas9 to make fine-tuned cuts in human DNA, Research Triangle Park, N.C.-based Locus is using a version of CRISPR, called CRISPR/Cas3, that acts more like a chainsaw, tearing up precisely targeted bacterial DNA. Investors include Tencent Holdings, Abstract Ventures, and the North Carolina Biotechnology Center.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment